Document:

Exhibit 10.4

 

Execution version

 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

[*****] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 

2019 AMENDMENT

 

TO GLOBAL MASTER SERVICES AGREEMENT AND

 

TO SUPPLY AGREEMENT

 

This Amendment (“2019 Amendment”) to the Global Master Services Agreement dated 1 January 2015 (“MSA”) and the Supply Agreement dated 1 January 2016 (“Supply Agreement”) is entered into as of 2 July, 2018 by and between

 

(1)                                 Shire International GmbH, a Swiss limited liability company having its registered office at Zählerweg 10, 6301 Zug, Switzerland (“Shire International”);

 

(2)                                 Shire Pharmaceuticals Ireland Ltd., an Irish limited liability company having its registered office at Block 2 & 3 Miesian Plaza, 50 – 58 Baggot Street Lower, Dublin 2, Ireland (“SPIL”); and

 

(3)                                 Centogene AG, a German stock corporation incorporated under the laws of the Federal Republic of Germany with principal office in Restock, registered with the district court (‘Amtsgericht’) in Rostock under HRB 13225 and having a business address at Am Strande 7, 18055 Restock, Germany (“Centogene”).

 

PREAMBLE

 

(A)                               Shire International and Centogene have entered into the MSA under which Centogene provides certain diagnostic testing services on the basis of dried-blood-spot (DBS) cards for the purpose of identifying patients suffering from lysosomal storage and other rare diseases to Shire International and its affiliates.

 

(B)                               In addition to the MSA, SPIL and Centogene have entered into the Supply Agreement under which Centogene (i) develops DBS test kits for the use in certain countries as required by SPIL on the basis of Centogene’s existing DBS test kits, (ii) manufactures such DBS test kits and (iii) supplies SPIL and its affiliates with such DBS test kits.

 

(C)                               On 8 March 2016, Shire International and Centogene entered into an amendment of the MSA under which Shire International and Centogene agreed, inter alia, on a flat fee for the performance of diagnostic services for the year 2016 (“2016 Amendment”). In a side letter to the MSA dated 24 November 2016, Shire International and Centogene agreed on certain additional commercial aspects with respect to the year 2016. On 3 May 2017, Shire International, SPIL and Centogene entered into an amendment of the MSA under which Shire International, SPIL and Centogene agreed, inter alia, on a flat fee for the performance of diagnostic services for the years 2017 and 2018 (“2017 Amendment”).

 

 

(D)                               Shire International, SPIL and Centogene now wish to agree on certain financial and other aspects of their cooperation going forward.

 

Now, therefore, Shire International, SPIL and Centogene, intending to be legally bound, hereby agree to amend the MSA and the Supply Agreement as follows:

 

 

DEFINITIONS

 

In this 2019 Amendment any capitalized terms shall have the meaning set forth in the MSA and the Supply Agreement (both as amended from time to time), unless a term is specifically defined under this 2019 Amendment.

 

1.                                      ANNUAL FLAT FEE

 

1.1.                            Annual Flat Fee.  The Parties agree to amend Section 3.6 of the MSA with respect to the calendar year 2019 as follows:

 

Subject to the below, Shire International will make an annual lump sum payment of € [*****] ([*****] Euro) to Centogene for the performance of [*****] of Diagnostic Tests for Morbus Fabry, Morbus Gaucher, Morbus Hunter, MPS1, MPS2, MPS3, MPS4, MPS6 and MPS7 in the calendar year 2019 (“Annual Flat Fee”). The financial terms of the Annual Flat Fee as well as other financial assumptions under the MSA and Supply Agreement are set forth in more detail in Appendix 1 to this 2019 Amendment. Centogene hereby expressly waives any payment claims for Excess Diagnostic Tests under Section 3.6(c) of the MSA; provided, however, that only the first [*****] Diagnostic Tests for MPS1, MPS3, MPS4, MPS6 and MPS7 performed in 2019 will be included in the Annual Flat Fee. Any additional Diagnostic Tests for MPS1, MPS3, MPS4, MPS6 and MPS7 will be invoiced and paid in accordance with Sec. 3.6 (c) of the MSA.

 

1.2.                            Diagnostic Test and Prices.  The Parties agree to replace Exhibit 1 of the MSA (Diagnostic Tests and Prices) in its entirety with a new Exhibit 1 attached to this 2019 Amendment as Appendix 2. Parties acknowledge that the prices reflected therein have been increased as per Section 3.6(g) of the MSA.

 

1.3.                            Reporting.  The payment of the Annual Flat Fee does not relieve Centogene from its obligation under Section 3.4 of the MSA to provide Shire International with detailed monthly summaries of Diagnostic Services actually rendered in the previous month, in the form as attached as Appendix 3 to this 2019 Amendment, including the information on the testing of expired Contract DBS Test Kits as further detailed in the Side Letter between Shire International and Centogene dated 2 July 2018.

 

1.4.                            Upfront Payments.  Centogene will issue at the beginning of each calendar month, a preliminary invoice for a prorated amount of the Annual Flat Fee, i.e. an amount equal to 1/12 of each Annual Flat Fee. Shire International shall make payment within ten (10) Business Days upon receipt of a proper invoice.

 

2.                                      BUSINESS CONTINUITY PLAN

 

Finalization of BCP, the parties hereby attach the latest agreed version of the Business Continuity Plan in Appendix 4.

 

3.                                      OTHER TERMS

 

Other.  All other terms and conditions as set forth in the MSA and the Supply Agreement (as amended from time to time) shall remain in full force and effect.

 

[signature page follows]

 

 

	
Place:
    	
Zug,   Switzerland
    	
 
    	
 
    	
Place:
    	
Berlin
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
2   July 2018
    	
 
    	
 
    	
Date:
    	
06.07.2018
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
for and on behalf of 
    	
 
    	
 
    	
for and on behalf of 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Shire International GmbH
    	
 
    	
 
    	
Centogene AG
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
/s/ Renco Lenarca
    	
 
    	
 
    	
/s/ Richard   Stoffelen
    	
/s/ Frank   Volpers
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Renco   Lenarca
    	
 
    	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Proxy Holder
    	
 
    	
 
    	
Title: 
    	
CFO
    	
VP Legal
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
CENTOGENE   AG
    
	
 
    	
 
    	
 
    	
 
    	
Zimmerstraße   69
    
	
Place:
    	
Dublin, Ireland
    	
 
    	
 
    	
10117   Berlin / Germany
    
	
 
    	
 
    	
 
    	
 
    	
Tel.   +49 (0)30 213000-323
    
	
Date:
    	
2/7/2018
    	
 
    	
 
    	
Tel.   +49 (0)30 213000-328
    
	
 
    	
 
    	
 
    	
 
    	
Email:   office@centogene.com
    
	
 
    	
 
    	
 
    	
Web:   www.centogene.com
    
	
for and on behalf of
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Shire Pharmaceuticals Ireland Ltd.
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
/s/ Denis Ahern
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Denis Ahern
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Director
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
2/7/2018
    	
 
    	
 
    	
 
    	
 
    

 

 

Appendix 1

 

Annual Flat Fee

 

Annual flat fee of € [*****] for 2019, respectively, subject to following assumptions and clarifications as set out below:

 

Notwithstanding the concept of the flat fee, it is hereby clarified that if Centogene performs less than [*****] Diagnostic Tests in 2019, reconciliation will take place in the subsequent calendar year (2020). In the beginning of such subsequent calendar year, Centogene will issue a credit note, against which future Shire International invoices will be offset, for an amount equal to the difference between the annual flat fee and the value of actual tests performed invoiced at the prices set forth in Exhibit 1 of the MSA (Diagnostic Tests and Prices).

 

 

Appendix 2

 

Exhibit 1 (Diagnostic Tests and Prices)

 

The below prices include (where indicated) an additional technology access fee of € [*****] per tested sample.

 

	
Test/procedure
    	
 
    	
Price In € (net)
    	
 
    	
Technology Access Fee in
   € (net)
    
	
Gaucher
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
It a mutation in a family is found there will be an   additional charge
    	
 
    	
 
    	
 
    	
 
    
	
- sample processing
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- per exon
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- in total for homozygous mutation
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- in total for an heterozygous mutation
    	
 
    	
[*****] €
    	
 
    	
 
    
	
For a prenatal analysis there is an additional   charge
    	
 
    	
 
    	
 
    	
 
    
	
- sample processing
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- for contamination control with maternal material
    	
 
    	
[*****] €
    	
 
    	
 
    
	
Fabry
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
If a mutation In a family is found them will be an   additional charge
    	
 
    	
 
    	
 
    	
 
    
	
- sample processing
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- per exon
    	
 
    	
[*****] €
    	
 
    	
 
    
	
For a prenatal analysis there is an additional   charge
    	
 
    	
 
    	
 
    	
 
    
	
- sample processing
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- for contamination control with maternal material
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS II (Hunter Disease)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS Illa (SGSH)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    

 

 

	
MPS Illb (NAGLU)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS IIIc (HGSNAT)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS IIId (GNS)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MLD(SGSH)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS I and VI (prices for each)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS IV
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS VII
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    

 

 

Appendix 3

 

Proforma Monthly Report

 

1.              Monthly diagnostic test report (one line per test performed)

 

[*****]

 

 

Execution version

 

2.              Monthly Expired Contract DBS Test Kit report (one line per country and disease on expired cards received)

 

[*****]

 

 

Appendix 4

 

Business Continuity PlanEX-4.2

 Exhibit 4.2 

GALERA THERAPEUTICS, INC. 

SECOND AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 1.     Definitions
	  	 	1	 
		
	 2.     Registration Rights
	  	 	5	 
			
	             
	 	 2.1.   Demand Registration
	  	 	5	 
		 	 2.2.   Company Registration
	  	 	7	 
		 	 2.3.   Underwriting Requirements
	  	 	7	 
		 	 2.4.   Obligations of the Company
	  	 	8	 
		 	 2.5.   Furnish Information
	  	 	10	 
		 	 2.6.   Expenses of Registration
	  	 	10	 
		 	 2.7.   Delay of Registration
	  	 	10	 
		 	 2.8.   Indemnification
	  	 	11	 
		 	 2.9.   Reports Under Exchange Act
	  	 	13	 
		 	 2.10.  Limitations on Subsequent Registration Rights
	  	 	13	 
		 	 2.11.  “Market Stand-off”
Agreement
	  	 	14	 
		 	 2.12.  Restrictions on Transfer
	  	 	15	 
		 	 2.13.  Termination of Registration Rights
	  	 	16	 
		
	 3.     Information Rights.
	  	 	16	 
			
		 	 3.1.   Delivery of Financial Statements and Other Information
	  	 	16	 
		 	 3.2.   Inspection
	  	 	18	 
		 	 3.3.   Termination of Information Rights
	  	 	18	 
		 	 3.4.   Confidentiality
	  	 	18	 
		
	 4.     Rights to Future Stock Issuances
	  	 	18	 
			
		 	 4.1.   Right of First Offer
	  	 	18	 
		 	 4.2.   Termination
	  	 	20	 
		
	 5.     Additional Covenants
	  	 	20	 
			
		 	 5.1.   Insurance
	  	 	20	 
		 	 5.2.   Employee Agreements
	  	 	20	 
		 	 5.3.   Employee Stock
	  	 	20	 
		 	 5.4.   Matters Requiring Investor Director Approval
	  	 	20	 
		 	 5.5.   Board Matters
	  	 	22	 
		 	 5.6.   Successor Indemnification
	  	 	22	 
		 	 5.7.   Termination of Covenants
	  	 	22	 
		 	 5.8.   Right to Conduct Activities
	  	 	22	 
		 	 5.9.   Board Observation Rights
	  	 	23	 
		 	 5.10.  Anti-Corruption
	  	 	23	 
		
	6.     Miscellaneous	  	 	24	 
			
		 	 6.1.   Successors and Assigns
	  	 	24	 
		 	 6.2.   Governing Law
	  	 	24	 
		 	 6.3.   Counterparts
	  	 	24	 

  
 i 

							
		 	 6.4.   Titles and Subtitles
	  	 	24	 
		 	 6.5.   Notices
	  	 	24	 
		 	 6.6.   Amendments and Waivers
	  	 	25	 
		 	 6.7.   Severability
	  	 	25	 
		 	 6.8.   Aggregation of Stock
	  	 	25	 
		 	 6.9.   Entire Agreement
	  	 	26	 
		 	 6.10.  Dispute Resolution
	  	 	26	 
		 	 6.11.  WAIVER OF JURY TRIAL
	  	 	26	 
		 	 6.12.  Dispute Resolution Fees
	  	 	26	 
		 	 6.13.  Delays or Omissions
	  	 	27	 
		 	 6.14.  Acknowledgment
	  	 	27	 
		 	 6.15.  Prior Agreement
	  	 	27	 
		 	 6.16.  Tekla Funds
	  	 	27	 

 Schedule A  -   Schedule of Investors 

  
 ii 

 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 30th day of August, 2018, by and among Galera Therapeutics, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is
referred to in this Agreement as an “Investor.” 
 RECITALS 

WHEREAS, the Company and certain of the Investors (the “Exisiting Stockholders”) entered into an Amended and Restated
Investors’ Rights Agreement, dated October 1, 2015, as amended by that First Amendment to the Amended and Restated Investors’ Rights Agreement, dated January 21, 2016, as amended by that Second Amendment to the Amended and
Restated Investors’ Rights Agreement, dated November 15, 2016 (as amended, the “Prior Agreement”); 

WHEREAS, the Company and certain of the Investors (the “Purchasers”) are parties to the Series C Preferred Stock
Purchase Agreement of even date herewith (as may be amended from time to time, the “Purchase Agreement”); 

WHEREAS, Section 6.6 of the Prior Agreement provides that the Prior Agreement may be amended by the written
consent of the Company, (a) the holders of a majority of the Registrable Securities then outstanding, and (b) at least three of New Enterprise Associates 14, L.P., Novartis BioVentures Ltd., Novo Holdings A/S, and Sofinnova Venture
Partners IX, L.P. so long as each of such holders owns at least 2,500,000 shares of Registrable Securities (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization) ((a) and
(b) the “Prior Requisite Holders”); 
 WHEREAS, the Existing Stockholders executing this Agreement constitute
the Prior Requisite Holders on the date hereof; and 
 WHEREAS, in order to induce the Company to enter into the Purchase Agreement
and to induce the Purchasers to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company desire to amend and restate the Prior Agreement and hereby agree that this Agreement shall govern the rights of the
Investors to cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set
forth in this Agreement. 
 NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions.For purposes of this Agreement: 

1.1. “Affiliate” and correlative terms mean, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, investment adviser, officer,director or trustee of such Person or any venture capital fund or
registered investment company now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment adviser with, such Person. 

  
 1 

 1.2. “Clarus Funds” means, collectively, Clarus IV-A, L.P., Clarus IV-B, L.P., Clarus IV-C, L.P., Clarus IV-D, L.P. together with each of its
successors and assigns Affiliated with Clarus IV GP, LLC. 
 1.3. “Common Stock” means shares of the Company’s common
stock, par value $0.001 per share. 
 1.4. “Competitor” means a competitor of the Company, as reasonably determined by the
Board of Directors, including a majority of the Preferred Directors; provided, however, that (i) Novartis Bioventures Ltd. and its Affiliates that are engaged in the business of the Novartis Venture Fund (collectively, the “NBV
Investors”) shall not be deemed to be Competitors for purposes of this definition solely because of any activities undertaken by Novartis AG or any of its Affiliates who are not otherwise NBV Investors; and (ii) Novo Holdings A/S shall
not be deemed a Competitor for purposes of this definition solely because of any activities undertaken by Novo Nordisk A/S or any of its Affiliates. 

1.5. “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under
the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a
material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the
Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.6. “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.7. “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.8. “Excluded Registration”
means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

  
 2 

 1.9. “FOIA Party” means a Person that, in the reasonable determination of
the Board of Directors, may be subject to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552
(“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement. 

1.10. “Form S-1” means such form under the Securities Act as in effect on the
date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.11. “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
 1.12. “GAAP” means generally accepted
accounting principles in the United States. 
 1.13. “Holder” means any holder of Registrable Securities who is a party to
this Agreement. 
 1.14. “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent,
spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.15. “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 1.16. “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 1.17. “Key Employee” means any employee of the Company at the level of vice president or above, and any other employee
who develops, invents, programs or designs any Company Intellectual Property. 
 1.18. “Major Investor” means any Investor
that, individually or together with such Investor’s Affiliates, holds at least 2,000,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected
after the date hereof). Notwithstanding the foregoing, Blackwell Partners LLC—Series A shall also be considered a “Major Investor”. 

1.19. “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. For the avoidance of doubt, any royalty
interest in the Company’s products in any form shall not be equity securities under this Agreement. 

  
 3 

 1.20. “Person” means any individual, corporation, partnership, trust,
limited liability company, association or other entity. 
 1.21. “Preferred Director” means any director of the Company that
the holders of the Preferred Stock are entitled to elect pursuant to the Company’s Certificate of Incorporation. 
 1.22.
“Preferred Stock” means the Series A Preferred Stock, the Series B Preferred Stock, the Series B-1 Preferred Stock, Series B-2 Preferred Stock and
Series C Preferred Stock. 
 1.23. “Registrable Securities” means (i) the Common Stock issuable or issued upon
conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof;
and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares
referenced in clauses (i), (ii) and (iii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to
Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.24. “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of
outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.25. “Restricted Securities” means the securities of the Company required to bear the legend set forth in Subsection
2.12(b) hereof. 
 1.26. “SEC” means the Securities and Exchange Commission. 

1.27. “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.28. “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.29. “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.30. “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection 2.6. 

  
 4 

 1.31. “Series A Preferred Stock” means shares of the Company’s Series
A Preferred Stock, par value $0.001 per share. 
 1.32. “Series B Preferred Stock” means shares of the Company’s Series
B Preferred Stock, par value $0.001 per share. 
 1.33. “Series B-1 Preferred Stock”
means shares of the Company’s Series B-1 Preferred Stock, par value $0.001 per share. 
 1.34.
“Series B-2 Preferred Stock” means shares of the Company’s Series B-2 Preferred Stock, par value $0.001 per share. 

1.35. “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.001 per share. 

1.36. “Requisite Holders” means (a) the holders of a majority of the Registrable Securities then outstanding, and
(b) at least three of the Clarus Funds, New Enterprise Associates 14, L.P., Novartis BioVentures Ltd., Novo Holdings A/S, and Sofinnova Venture Partners IX, L.P. so long as each of such holders owns at least 2,500,000 shares of Registrable
Securities (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization) (such holders, the “Major Holders”); provided that if one or more of the Clarus Funds, New
Enterprise Associates 14, L.P., Novartis Bioventures Ltd., Novo Holdings A/S, or Sofinnova Venture Partners IX, L.P. shall cease to be a Major Holder, then a majority of the remaining Major Holders shall be required pursuant to clause (b) of
the definition of “Requisite Holders”. 
 2. Registration Rights.The Company covenants and agrees as follows: 

2.1. Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the
date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities
then outstanding that the Company file a Form S-1 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling
Expenses, of at least $10.0 million, then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders;
and (ii) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities
Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such
Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection 2.1(c) and Subsection 2.3. 

  
 5 

 (b) Form S-3 Demand. If at any time when it
is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty percent (20%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $1.0 million, then the Company
shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the
date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any
other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection 2.1(c) and Subsection 2.3.

 (c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for such
registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition,
corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the
Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall
be tolled correspondingly, for a period of not more than sixty (60) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than twice in any twelve (12) month
period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such sixty (60) day period other than an Excluded Registration. 

(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a), (i)
during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration,
provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Subsection
2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection
2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b), (i) during the period that is thirty (30) days before the Company’s good faith estimate of
the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such
registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall
not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders constituting a majority of
Registrable 

  
 6 

 
Securities then held by such Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand
registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2. Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for
stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give
each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all
of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective
date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with
Subsection 2.6. 
 2.3. Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and
shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting; provided, however, the liability of any such Holder shall be several and not
joint, and limited to an amount equal to the net proceeds from the offering received by such Holder. Notwithstanding any other provision of this Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that
marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable
Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each
Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other
securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100
shares. 

  
 7 

 (b) In connection with any offering involving an underwriting of shares of the
Company’s capital stock pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon
between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the
offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success
of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among
the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable
Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be
reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and
no other stockholder’s securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation,
the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of
any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all
Persons included in such “selling Holder,” as defined in this sentence. 
 2.4. Obligations of the Company. Whenever
required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time
equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of

  
 8 

 
Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such
one hundred twenty (120) day period shall be extended for up to an additional sixty (60) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available for
inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all
financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller,
underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

  
 9 

 (i) notify each selling Holder, promptly after the Company receives notice thereof, of the
time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5. Furnish Information. It shall be a condition precedent to
the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself,
the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6. Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration
proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such
expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to
Subsection 2.1(a) or Subsection 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company
from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their
right to one registration pursuant to Subsection 2.1(a) or Subsection 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the
Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 
 2.7. Delay of
Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 2. 

  
 10 

 2.8. Indemnification. If any Registrable Securities are included in a
registration statement under this Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and
hold harmless each selling Holder, and the partners, members, officers, directors, trustees and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such
Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the
indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably
withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder,
underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent
permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company
within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such
underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of
such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with
investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in
settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any
Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful
misconduct by such Holder. 
 (c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the
commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other
indemnifying party to which 

  
 11 

 
notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially
prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection
2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either
(i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent
jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such
case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the
aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party
in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of
the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (x) no
Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s
liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid
by such Holder), except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent that
the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement
shall control. 

  
 12 

 (f) Unless otherwise superseded by an underwriting agreement entered into in connection
with the underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this
Section 2, and otherwise shall survive the termination of this Agreement. 
 2.9. Reports Under Exchange
Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or
pursuant to a registration on Form S-3, the Company shall: 
 (a) make and keep available adequate
current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and
such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without
registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10. Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without
the prior written consent of the Requisite Holders, enter into any agreement with any holder or prospective holder of any securities of the Company that would (i) allow such holder or prospective holder to include such securities in any
registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable
Securities of the Holders that are included or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder. 

  
 13 

 2.11. “Market
Stand-off” Agreement. (a) Without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the
registration by the Company of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3 and
ending on the date specified by the Company and the managing underwriter, each Holder hereby agrees that it will not, for a period not to exceed one hundred eighty (180) days in the case of the IPO; and each Affiliated Holder hereby agrees that
it will not, for a period not to exceed ninety (90) days in the case of any registration other than the IPO; or, in each case such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on
(1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor
provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose
of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such
offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above
is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. For purposes of this Subsection 2.11, an “Affiliated Holder” is a Holder that holds 10% or more of the Company’s outstanding Common
Stock or that has an Affiliate as a member of the Company’s Board of Directors at the time such registration statement is filed. For the avoidance of doubt, the foregoing 90 day lockup period referenced in this Subsection 2.11 shall
apply only to Affiliated Holders and not to any other Holders. 
 (b) The foregoing provisions of this Subsection 2.11 shall not
apply to (i) the sale of any shares to an underwriter pursuant to an underwriting agreement, (ii) any shares purchased in the IPO or in the open market following the IPO or (iii) the transfer of any shares to an Affiliate of a Holder
or to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the Affiliate or the trustee of the trust, as applicable, agrees to be bound in writing by the restrictions set forth herein, and
provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to
obtain a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters
in connection with such registration are intended third party beneficiaries of this Subsection 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees
to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or
termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. 

  
 14 

 2.12. Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Each certificate or instrument representing (i) the Preferred
Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar
event, shall (unless otherwise permitted by the provisions of Subsection2.12(c)) be stamped or otherwise imprinted with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SHARES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A
COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of each certificate representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the
provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the
Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail
and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to
the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such
Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that
the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell,

  
 15 

 
pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no
action” letter (x) in any transaction in compliance with SEC Rule 144 or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee
agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate or instrument evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the
appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to
establish compliance with any provisions of the Securities Act. 
 2.13. Termination of Registration Rights. The right of any Holder
to request registration or inclusion of Registrable Securities in any registration pursuant to Subsection 2.1 or Subsection 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation; 

(b) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares
without limitation during a three-month period without registration; and 
 (c) the fifth
(5th) anniversary of the IPO. 
 3. Information Rights. 

3.1. Delivery of Financial Statements and Other Information. The Company shall deliver to each Major Investor (provided that such Major
Investor is not a Competitor): 
 (a) as soon as practicable, but in any event within one hundred eighty (180) days after the end of
each fiscal year of the Company beginning with the fiscal year ending December 31, 2018, (1) financial statements of the Company for such fiscal year containing (i) a balance sheet as of the end of such year, (ii) statements of income
and of cash flows for such year, and a comparison between the actual amounts as of and for such fiscal year and the comparable amounts for the prior year and (iii) a statement of stockholders’ equity as of the end of such year, all such
financial statements audited and certified by independent public accountants of recognized standing selected by the Company’s Board of Directors, and (2) a comparison of the actual results to those included in the Budget (as defined in
Subsection 3.1(e)) for such year; 
 (b) as soon as practicable, but in any event within
forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an
unaudited balance sheet, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto
that may be required in accordance with GAAP); 

  
 16 

 (c) as soon as practicable, but in any event within forty-five (45) days after the end
of each quarter of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period,
the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock
options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief
executive officer of the Company as being true, complete, and correct; 
 (d) as soon as practicable, but in any event within thirty
(30) days of the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with
GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(e) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next
fiscal year (collectively, the “Budget”), approved by the Board of Directors, including a majority of the Preferred Directors, and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow
for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 
 (f) such other
information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this
Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless such confidential information is covered by an enforceable confidentiality agreement,
in form acceptable to the Company) or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this
Subsection 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC
rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable
efforts to cause such registration statement to become effective. 

  
 17 

 3.2. Inspection. The Company shall permit each Major Investor (provided that
such Major Investor is not a Competitor), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its
officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that
it reasonably and in good faith considers to be a trade secret or confidential information (unless such confidential information is covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which
would adversely affect the attorney-client privilege between the Company and its counsel. 
 3.3. Termination of Information
Rights. The covenants set forth in Subsection 3.1 and Subsection 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes
subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs
first. 
 3.4. Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge,
or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration
statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.4 by such Investor), (b) is or has been independently developed or conceived
by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the
Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its
investment in the Company and to the extent necessary in connection with such Investor’s tax filings, financial reporting (including with the SEC) and accounting matters; (ii) to any prospective purchaser of any Registrable Securities from
such Investor, if such prospective purchaser agrees in writing with the Company to be bound by the provisions of this Subsection 3.4; (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the
ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law,
provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

4. Rights to Future Stock Issuances.  

4.1. Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if
the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Investor. An Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems
appropriate, among (i) itself and (ii) its Affiliates; provided that, each such Affiliate: (x) is not a 

  
 18 

 
Competitor or a FOIA Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of Directors, (y) agrees to enter into this Agreement and each of the
Voting Agreement and Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an “Investor” under each such
agreement (provided that, any Competitor or FOIA Party shall not be entitled to any rights as a Major Investor under Subsections 3.1 and 3.2 hereof), and (z) agrees to purchase, together with the applicable
Investor and any of its other Affiliates to whom this right is apportioned, an aggregate of at least such number of New Securities as are allocable hereunder to the Investor holding the fewest number of Preferred Stock and any other Derivative
Securities. 
 (a) The Company shall give notice (the “Offer Notice”) to each Investor, stating (i) its bona fide
intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Preferred Stock issued and held by such Investor bears to the total Preferred Stock issued
and outstanding. At the expiration of such twenty (20) day period, the Company shall promptly notify each Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any
other Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to
the number of shares specified above, up to that portion of the New Securities for which Investors were entitled to subscribe but that were not subscribed for by the Investors which is equal to the proportion that the Preferred Stock issued and held
by such Fully Exercising Investor bears to the Preferred Stock issued and held by all Fully Exercising Investors who wish to purchase such unsubscribed shares.The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the
later of one hundred and twenty (120) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 

(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b),
the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not
less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated
within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this Subsection 4.1.

 (d) The right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the
Company’s Certificate of Incorporation); and (ii) shares of Common Stock issued in the IPO. 

  
 19 

 4.2. Termination. The covenants set forth in Subsection 4.1 shall
terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or
(iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

5. Additional Covenants 

5.1. Insurance. The Company shall use its commercially reasonable efforts to maintain Directors and Officers liability insurance in an
amount and on terms and conditions satisfactory to the Board of Directors, including a majority of the Preferred Directors, until such time as the Board of Directors, including a majority of the Preferred Directors, determines that such insurance
should be discontinued. Such policy shall not be cancelable by the Company without prior approval by the Board of Directors, including a majority of the Preferred Directors. 

5.2. Employee Agreements. The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or
engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement and (ii) each Key Employee
to enter into a one (1) year noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of Directors; provided, that the nondisclosure and proprietary rights assignment agreements and noncompetition and
nonsolicitation agreements entered into prior to or concurrently with the date hereof are deemed to be in the form approved by the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole
or in part, any of the above-referenced agreements in a manner that materially affects the applicable service provider’s nondisclosure, proprietary rights assignment, noncompetition or nonsolicitation obligations or any restricted stock or
stock repurchase agreement between the Company and any employee, without the consent of a majority of the Preferred Directors. 
 5.3.
Employee Stock. Unless otherwise approved by the Board of Directors, including a majority of the Preferred Directors, all future employees of the Company who purchase, receive options to purchase, or receive awards of shares of the
Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for vesting of shares over a four (4) year period, with the first twenty five percent (25%) of such
shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months;
provided, that such vesting would be accelerated in the event of a termination of employment without cause or resignation for good reason within twelve months following a change of control.  

5.4. Matters Requiring Investor Director Approval. So long as the holders of Preferred Stock are entitled to elect a Preferred Director,
the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must include the affirmative vote of a majority of the Preferred Directors:  

  
 20 

 (a) make, or permit any subsidiary to make, any loan or advance to, or own any stock or
other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 
 (b)
make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under
the terms of an employee stock or option plan approved by the Board of Directors; 
 (c) guarantee, directly or indirectly, or permit any
subsidiary to guarantee, directly or indirectly, any indebtedness except for trade accounts of the Company or any subsidiary arising in the ordinary course of business, in an aggregate amount not to exceed $50,000; 

(d) make, or permit any subsidiary to make, any investment inconsistent with any investment policy approved by the Board of Directors; 

(e) incur, or permit any subsidiary to incur, any indebtedness in excess of $100,000 in the aggregate among the Company and all of its
subsidiaries that is not already included in a budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business; 

(f) otherwise enter into or be a party to, or permit any subsidiary to enter into or be a party to, any transaction with any director,
officer, or employee of the Company or any subsidiary or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person; 

(g) hire, terminate, or change the compensation of the executive officers of the Company or any subsidiary, including approving any option
grants or stock awards to such executive officers; 
 (h) change the principal business of the Company, enter new lines of business, or exit
the current line of business, or permit any subsidiary to do any of the foregoing; 
 (i) acquire, sell, assign, license, pledge, or
encumber material technology or intellectual property, or permit any subsidiary to do any of the foregoing, other than licenses granted in the ordinary course of business; 

(j) enter into, or permit any subsidiary to enter into, any corporate strategic relationship involving the payment, contribution, or
assignment by the Company or any subsidiary or to the Company or any subsidiary of money or assets greater than $100,000; 
 (k) create or
authorize the creation of any stock option or other equity incentive plan or arrangement, increase the number of shares available for issuance under any such plan or arrangement or otherwise amend, waive or terminate any of the terms and provisions
of such plan or arrangement, or permit any subsidiary to do any of the foregoing with respect to any equity interests in such subsidiary; or 

  
 21 

 (l) enter into any material acquisition, transfer, license or other disposition of
intellectual property rights or other assets outside the ordinary course of business or cause any subsidiary of the Company to do any of the foregoing. 

5.5. Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors
shall meet at least quarterly in accordance with an agreed-upon schedule. All meetings may take place by teleconference or videoconference. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel expenses incurred in connection with attending meetings of the Board of Directors (including any committee thereof). The Company shall cause to be established, as soon as practicable
after such request, and will maintain, audit and compensation committees, each of which shall consist solely of non-management directors and include at least three Preferred Directors. Each Preferred Director
shall be entitled in such director’s discretion to be a member of (or an observer of) any committee of the Board of Directors. 
 5.6.
Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the
extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such
transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 

5.7. Termination of Covenants. The covenants set forth in this Section 5, except for Subsection
5.6, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the
Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first.  

5.8. Right to Conduct Activities. The Company hereby agrees and acknowledges that Novo Holdings A/S, Novartis BioVentures Ltd.,
New Enterprise Associates 14, L.P., NEA Ventures 2012 Limited Partnership, Correlation Ventures, L.P., Sofinnova Venture Partners IX, L.P., the Clarus Funds, the Tekla Funds (as defined in Section 6.16), Rock Springs Capital Master Fund LP, RA
Capital Healthcare Fund, L.P., Blackwell Partners LLC—Series A, Pivotal Alpha Limited, Adage Capital Partners, LP and HBM Healthcare Investments (Cayman) Ltd. (together with their affiliates, the “Venture Fund Purchasers”) are
professional investment funds, and as such invest in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees
that, to the extent permitted under applicable law, the Venture Fund Purchasers shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by the Venture Fund Purchasers in any entity competitive with the
Company, or (ii) actions taken by any partner, officer or other representative of, or advisor to, the Venture Fund Purchasers to assist any such competitive company, whether or not such action was taken as a member of the board of
directors of such competitive company or otherwise, and whether or not such action has a 

  
 22 

 
detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the
Company’s confidential information obtained pursuant to this Agreement or through participation on the Board of Directors, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the
Company.  
 5.9. Board Observation Rights. 

(a) For so long as Enso Ventures 2 Limited (“Enso”) holds at least 1,000,000 shares of Series
B-1 Preferred Stock (as adjusted to stock splits, stock dividends or any subdivision of shares), it shall have the right to designate one individual to attend each regularly scheduled, special and other
meeting (including telephonic meetings) of the Board of Directors (including each committee of the Board of Directors) of the Company as a non-voting observer (the “Observer”). Without the
consent of a majority of the Board of Directors, the Observer shall not be permitted to participate in any meeting beyond his or her capacity as a silent observer. The Observer shall not be entitled to the board observation rights described in this
Section 5.9(a) unless and until the Observer signs a confidentiality agreement in a form reasonably acceptable to the Company and Enso, pursuant to which the Observer agrees to hold in confidence and trust all information
provided or obtained at or in connection with any such meeting that he or she has a right to observe. The Company may withhold any information and exclude any such Observer from any meeting or portion thereof if access to such information or
attendance at such meeting could, in the determination of Company’s counsel, adversely affect the attorney-client privilege between the Company and its counsel, or could result in disclosure of trade secrets or relates to a point of a conflict
of interest, or if such individual is employed by or affiliated with any competitor of the Company.  
 (b) For so long as Tekla
Funds holds at least 1,000,000 shares of Series C Preferred Stock (as adjusted to stock splits, stock dividends or any subdivision of shares), it shall have the right to designate one individual to attend each regularly scheduled, special and other
meeting (including telephonic meetings) of the Board of Directors (including each committee of the Board of Directors) of the Company as a non-voting observer (the “Tekla Observer”).
Without the consent of a majority of the Board of Directors, the Tekla Observer shall not be permitted to participate in any meeting beyond his or her capacity as a silent observer. The Tekla Observer shall not be entitled to the board observation
rights described in this Section 5.9(b) unless and until the Observer signs a confidentiality agreement in a form reasonably acceptable to the Company and Tekla Funds, pursuant to which the Tekla Observer agrees to hold in
confidence and trust all information provided or obtained at or in connection with any such meeting that he or she has a right to observe. The Company may withhold any information and exclude any such Tekla Observer from any meeting or portion
thereof if access to such information or attendance at such meeting could, in the determination of Company’s counsel, adversely affect the attorney-client privilege between the Company and its counsel, or could result in disclosure of trade
secrets or relates to a point of a conflict of interest, or if such individual is employed by or affiliated with any competitor of the Company. 

5.10. Anti-Corruption. The Company covenants to comply with the FCPA or any other anti-bribery or anti-corruption law applicable
to the Company or its subsidiaries (such as Part 12 of the United States Anti-Terrorism, Crime and Security Act of 2001; the United States Money Laundering Control Act of 1986; the United States International Money Laundering Abatement and
Anti-Terrorist Financing Act of 2001; and the United States Foreign Corrupt Practices Act, as amended. 

  
 23 

 6. Miscellaneous 

6.1. Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the
ownership interests of which are owned wholly by, such Holder or any such Immediate Family Members; or (iii) after such transfer, holds at least 500,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock
dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable
Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the
provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a
Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that
all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving
notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
herein. 
 6.2. Governing Law. This Agreement shall be governed by the internal law of the State of Delaware. 

6.3. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly
delivered and be valid and effective for all purposes. 
 6.4. Titles and Subtitles. The titles and subtitles used in this
Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.5. Notices.
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when
sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during 

  
 24 

 
normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid;
or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All
communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such
email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Subsection 6.5. If notice is given to the Company, a copy shall also be sent to C. Brendan Johnson, Esq., Bryan Cave Leighton
Paisner LLP, 211 North Broadway, Suite 3600, St. Louis, MO 63102. 
 6.6. Amendments and Waivers. Any term of this Agreement
may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the Requisite Holders; provided
that if an amendment or a waiver adversely affects one series of Preferred Stock, then such waiver or amendment will be effective only with the written consent of the Company and the holders of a majority of the class of Preferred Stock so affected;
provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection
2.12(c) shall be deemed to be a waiver); provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, (a) Sections
5.9(a) and (b) of this Agreement may not be amended or terminated and the observance of thereof may not be waived with respect to the Observer without the written consent of Enso and with respect to the Tekla Observer without the written
consent of the Tekla Funds (defined below), and (b) this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such
amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors
in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). The Company shall give prompt notice of any amendment
or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6 shall be binding on
all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or
continuing waiver of any such term, condition, or provision.  
 6.7. Severability. In case any one or more of the
provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal,
or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8. Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for
the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

  
 25 

 6.9. Entire Agreement. This Agreement (including any Schedules and Exhibits
hereto), the Certificate and the other Transaction Agreements (as defined in the Purchase Agreement) constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or
oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 
 6.10. Dispute
Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of New Castle County, Delaware and to the jurisdiction of the United States District Court for the District of Delaware
for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of New
Castle County, Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is
not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or
proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be
entitled to reasonable attorney’s fees, costs, and disbursements in addition to any other relief to which such party may be entitled. 

6.11. WAIVER OF JURY TRIAL. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR
ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION AGREEMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT
MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS
SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND
THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.12. Dispute
Resolution Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs, and disbursements in addition to any
other relief to which such party may be entitled. 

  
 26 

 6.13. Delays or Omissions. No delay or omission to exercise any right, power,
or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a
waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.14. Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital investing and therefore
review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or
in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company. 

6.15. Prior Agreement. The Prior Agreement is hereby amended and restated in its entirety in the manner set forth in this
Agreement and such Prior Agreement is hereby terminated. 
 6.16. Tekla Funds. A copy of the Declaration of Trust, as amended
and restated, for each of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund (collectively, the “Tekla Funds”) is on file with the Secretary of State of The
Commonwealth of Massachusetts, and notice is hereby given that this Agreement is executed on behalf of the Tekla Funds by an officer or trustee of the Tekla Funds in his or her capacity as an officer or trustee of the Tekla Funds, and not
individually and that the obligations of or arising out of this Agreement are not binding upon any of the trustees, officers or shareholders individually but are binding only upon the assets and property of each of the respective Tekla Funds. 

[Remainder of Page Intentionally Left Blank] 

  
 27 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

							
	COMPANY:	 		 	Galera Therapeutics, Inc.
				
		 		 	By:	 	 /s/ Mel Sorensen

		 		 	Name: Mel Sorensen
		 		 	Title: President and Chief Executive Officer
			
		 		 	Address:
		 		 	2 West Liberty Boulevard, Suite 110
		 		 	Malvern, PA 19355

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

							
	INVESTOR:	 		 	Clarus IV-A, L.P.
		 		 	 By: Clarus IV GP, L.P.,
 its General
Partner

		 		 	 By: Clarus IV GP, LLC,
 its General
Partner

			
		 		 	 /s/ Emmett T. Cunningham

		 		 	Name:	 	Emmett T. Cunningham, MD
		 		 	Title:	 	Managing Director
			
		 		 	Clarus IV-B, L.P.
		 		 	 By: Clarus IV GP, L.P.,
 its General
Partner

		 		 	 By: Clarus IV GP, LLC,
 its General
Partner

			
		 		 	 /s/ Emmett T. Cunningham

		 		 	Name:	 	Emmett T. Cunningham, MD
		 		 	Title:	 	Managing Director
			
		 		 	Clarus IV-C, L.P.
		 		 	 By: Clarus IV GP, L.P.,
 its General
Partner

		 		 	 By: Clarus IV GP, LLC,
 its General
Partner

			
		 		 	 /s/ Emmett T. Cunningham

		 		 	Name:	 	Emmett T. Cunningham, MD
		 		 	Title:	 	Managing Director
			
		 		 	Clarus IV-D, L.P.
		 		 	 By: Clarus IV GP, L.P.,
 its General
Partner

		 		 	 By: Clarus IV GP, LLC,
 its General
Partner

			
		 		 	 /s/ Emmett T. Cunningham

		 		 	Name:	 	Emmett T. Cunningham, MD
		 		 	Title:	 	Managing Director

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	TEKLA HEALTHCARE INVESTORS*
		
	By:	 	 /s/ Daniel R. Omstead

	Name:	 	Daniel R. Omstead, Ph.D.
	Title:	 	President

  

	*	 The name Tekla Healthcare Investors is the designation of the Trustees for the time being under an
Amended & Restated Declaration of Trust dated April 21, 1987, as amended, and all persons dealing with Tekla Healthcare Investors must look solely to the trust property for the enforcement of any claim against Tekla Healthcare
Investors, as neither the Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Healthcare Investors. 

 

			
	 TEKLA LIFE SCIENCES INVESTORS*

		
	By:	 	 /s/ Daniel R. Omstead

	Name:	 	Daniel R. Omstead, Ph.D.
	Title:	 	President

  

	*	 The name Tekla Life Sciences Investors is the designation of the Trustees for the time being under a
Declaration of Trust dated February 20, 1992, as amended, and all persons dealing with Tekla Life Sciences Investors must look solely to the trust property for the enforcement of any claim against Tekla Life Sciences Investors, as neither the
Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Life Sciences Investors. 

 

			
	 TEKLA HEALTHCARE OPPORTUNITIES FUND*

		
	By:	 	 /s/ Daniel R. Omstead

	Name:	 	Daniel R. Omstead, Ph.D.
	Title:	 	President

  

	*	 The name Tekla Healthcare Opportunities Fund is the designation of the Trustees for the time being under an
Amended & Restated Declaration of Trust dated June 11, 2014, and all persons dealing with Tekla Healthcare Opportunities Fund must look solely to the trust property for the enforcement of any claim against Tekla Healthcare
Opportunities Fund, as neither the Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Healthcare Opportunities Fund. 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 
			
	 TEKLA WORLD HEALTHCARE FUND*

		
	By:	 	 /s/ Daniel R. Omstead

	Name:	 	Daniel R. Omstead, Ph.D.
	Title:	 	President

  

	*	 The name Tekla World Healthcare Fund is the designation of the Trustees for the time being under an
Amended & Restated Declaration of Trust dated May 18, 2015, and all persons dealing with Tekla World Healthcare Fund must look solely to the trust property for the enforcement of any claim against Tekla World Healthcare Fund, as
neither the Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla World Healthcare Fund. 

SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

					
	 INVESTOR: 
	 	 SOFINNOVA VENTURE PARTNERS IX, L.P.

		 	By:	 	Sofinnova Management IX, L.L.C.
		 		 	Its General Partner
			
		 	By:	 	 /s/ Mike Powell

		 		 	Mike Powell, Managing Member

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

					
	INVESTOR:	 	NOVO HOLDINGS A/S
			
		 	By:	 	 /s/ Thomas Dyrberg

		 	Name: Thomas Dyrberg, under specific power of attorney
		 	Title:	 	Managing Partner

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

					
	INVESTOR:	 	Novartis BioVentures Ltd.
			
		 	By:	 	 /s/ Stephan Sandmeier

		 	Name:	 	Stephan Sandmeier
		 	Title:	 	Authorized Signatory
			
		 	By:	 	 /s/ Florian Muellershausen

		 	Name:	 	Florian Muellershausen
		 	Title:	 	Authorized Signatory

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

					
	INVESTOR:	 	New Enterprise Associates 14, L.P.
		 	By: NEA Partners 14, L.P., its general partner
		 	By: NEA 14 GP, LTD, its general partner
			
		 	By:	 	 /s/ Louis S. Citron

		 	Name:	 	Louis S. Citron
		 	Title:	 	Chief Legal Officer

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

					
	INVESTOR:	 	NEA Ventures 2012 Limited Partnership
		 	By:                     , its general partner
			
		 	By:	 	 /s/ Louis S. Citron

		 	Name:	 	Louis S. Citron
		 	Title:	 	Vice President

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

					
	INVESTOR:	 	Correlation Ventures, L.P.
		 	as nominee for
		 	Correlation Ventures, L.P.
		 	Correlation Ventures Executives Fund, L.P.
		
		 	By: Correlation Ventures GP, LLC
			
		 	By:	 	 /s/ David E. Coats

		 	Name:	 	David E. Coats
		 	Title:	 	Managing Member

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 INVESTOR:     

 

			
	RA CAPITAL HEALTHCARE FUND, L.P. 
	
	By: RA Capital Management, LLC
	Its: General Partner
		
	By:	 	 /s/ James Schneider

	Name:	 	James Schneider
	Title:	 	Authorized Signatory

  

			
	 Address:     RA Capital Management, LLC

		 	   20 Park Plaza

		 	   Suite 1200

		 	   Boston, MA 02116

		 	   Attn: General Counsel

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 INVESTOR:     

 

			
	BLACKWELL PARTNERS LLC – SERIES A
		
	By:	 	 /s/ Abayomi A. Adigun

	Name:	 	Abayomi A. Adigun
	Title:	 	Investment Manager, DUMAC, Inc.
		 	Authorized Signatory
		
	By:	 	 /s/ Jannine M. Lall

	Name:	 	Jannine M. Lall
	Title:	 	Controller, DUMAC, Inc.
		 	Authorized Signatory
	
	Address:    Blackwell Partners LLC – Series A
		 	     280 S. Mangum Street
		 	     Suite 210
		 	     Durham, NC 27701
		 	     Attn: XXX

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

							
	INVESTOR:	 		 	BioGenerator
				
		 		 	By:	 	 /s/ Eric Gulve

		 		 	Name:	 	Eric Gulve
		 		 	Title:	 	President

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

							
	INVESTOR:	 		 	Galera Angels LLC
				
		 		 	By:	 	 /s/ Robert Calcaterra

		 		 	Name:	 	Robert Calcaterra
		 		 	Title:	 	Managing Member

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

			
	INVESTOR:	  	/s/ Robert A.
Beardsley                                        
                            
		  	Robert A. Beardsley

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

			
	INVESTOR:	  	 /s/ Dennis
Riley                                        
                                    

Dennis Riley

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

			
	INVESTOR:	  	 /s/ Jeffery
Keene                                        
                                        

Jeffery Keene

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

							
	INVESTOR:	 		 	The Catherine L. Matthes Trust
				
		 		 	By:	 	 /s/ Catherine L. Matthes

		 		 	Name:	 	Catherine L. Matthes

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

							
	INVESTOR:	 		 	Adage Capital Partners, LP
			
		 		 	By: Adage Capital Partners, GP, LLC, its General Partner
		 		 	By: Adage Capital Advisors, LLC its Managing Member
				
		 		 	        By:	 	 /s/ Dan Lehan

		 		 	        Name:	 	Dan Lehan
		 		 	        Its:	 	Chief Operating Officer

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

									
	INVESTOR: 	  		  	HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD. 
					
		  		  		  	            By:	  	 /s/ Jean-Marc LeSieur

		  		  		  	            Name:	  	Jean-Marc LeSieur
		  		  		  	            Title:	  	Managing Director

									
					
		  	                    	  		  	ADDRESS:	  	Attention: XXX
		  		  		  		  	Governors Square, Suite #4-212-2
		  		  		  		  	23 Lime Tree Bay Avenue
		  		  		  		  	West Bay
		  		  		  		  	Grand Cayman, Cayman Islands

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

							
	INVESTOR: 	 		 	Rock Springs Capital Master Fund LP
		 		 	By: Rock Springs General Partner LLC, its general partner
				
		 		 	        By:	 	 /s/ Graham McPhail

		 		 	        Name:	 	Graham McPhail
		 		 	        Its:	 	Managing Member

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

							
	INVESTOR: 	 		 	Pivotal Alpha Limited
				
		 		 	        By:	 	 /s/ Sun Xintong     /s/ Tang Chun Wai Nelson

		 		 	        Name:	 	Sun Xintong     Tang Chun Wai Nelson
		 		 	        Its:	 	Directors

							
				
		 		 	            Address:	 	        c/o 23/F Nan Fung Tower
		 		 		 	        88 Connaught Road C
		 		 		 	        Central, Hong Kong
		 		 		 	        Attn: Terence Lam

 SIGNATURE PAGE TO SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

Investors 
 Clarus IV-A, L.P. 
 Clarus IV-B, L.P. 

Clarus IV-C, L.P. 

Clarus IV-D, L.P. 

101 Main Street, Suite 1210 
 Cambridge, MA 02142 

Attn: XXX 
 Email: XXX@clarusfunds.com 

With a copy to: 
 Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park, CA 94025 

Attn: XXX 
 Email: XXX@lw.com 

Tekla Healthcare Investors 
 Tekla Life Sciences
Investors 
 Tekla Healthcare Opportunities Fund 

Tekla World Healthcare Fund 
 c/o Tekla Capital Management
LLC 
 100 Federal Street, 19th Floor 
 Boston, MA 02110 

Attention: XXX 
 Telephone:
(XXX) XXX-XXXX 
 Facsimile: (XXX) XXX-XXXX 

Email: XXX@teklacap.com 
 With a copy (which shall not constitute
notice) to: 
 Reitler Kailas & Rosenblatt LLC 
 4
Independence Way, Suite 120 
 Princeton, NJ 08540 
 Attention:
XXX 
 Facsimile: (XXX) XXX-XXXX 

Email: XXX@reitlerlaw.com 
 Enso Ventures 2 Limited 

c/o Albecq Trust Company Limited 
 Suite 6, Provident House 

Havilland Street, St. Peter Port 
 Guernsey, GY1 2QE 

Sofinnova Venture Partners IX, L.P. 
 3000 Sand Hill Road,
Bldg. 4, Suite 250 
 Menlo Park, CA 94025 

 Novo Holdings A/S 

Tuborg Havnevej 19 

DK-2900 Hellerup 
 Denmark

 Attn: XXX 
 Email: XXX@novo.dk 

with a copy (which shall not constitute notice) to: 
 Novo
Ventures (US), Inc. 
 501 2nd Street, Suite 300 
 San
Francisco, CA 94107 
 Attention: XXX 
 Email:XXX@novo.dk
 
 Novartis BioVentures Ltd. 
 Novartis Campus,
Forum 1-1.32 
 Attn: Stephan Sandmeier 

CH-4056 Basel, Switzerland 

Email: XXX@novartis.com 
 With a copy to: 

Novartis Venture Fund 
 Attn: XXX 

100 Technology Square, Suite 3150 
 Cambridge, MA 02139 

Email: XXX@nvfund.com 
 New Enterprise Associates 14, L.P.

 1954 Greenspring Drive, Suite 600 
 Timonium, MD 21093

 Attn: XXX 
 Email: XXX@nea.com 

NEA Ventures 2012 Limited Partnership 
 1954 Greenspring
Drive, Suite 600 
 Timonium, MD 21093 
 Attn: XXX 

Email: XXX@nea.com 
 Correlation Ventures, L.P. 

9255 Towne Centre Drive, Suite 350 
 San Diego, CA 92121 

(XXX) XXX-XXXX Main 
 (XXX) XXX-XXXX Fax 

BioGenerator 
 20 South Sarah Street 

St. Louis, MO 63108 
 Galera Angels LLC 

148 Bon Chateau Drive 
 St. Louis, MO 63141 

 Northfork Grindstone Creek LLC 

c/o Marberry Eagle, CPAs, p.c. 
 414 E. Broadway, Suite 300 

Columbia, MO 65201 
 Robert A. Beardsley, PhD 

XXX 
 XXX 

Regina A. Buckler 
 XXX 

XXX 
 Jeffery Keene, PhD 

XXX 
 XXX 

The Catherine L. Matthes Trust 
 XXX 

XXX 
 Homer Pearce 

XXX 
 XXX 

Dennis Riley, PhD 
 XXX 

XXX 
 The Weiss Family Revocable Living Trust, Randy Herman
Weiss and Rose Gene Weiss, Trustees, Date of Trust: March 26, 2002, amended April 5, 2010 
 XXX 

XXX 
 RA Capital Healthcare Fund, L.P. 

RA Capital Management, LLC 
 20 Park Plaza 

Suite 1200 
 Boston, MA 02116 

Attn: General Counsel 
 Blackwell Partners LLC – Series A

 280 S. Mangum Street 
 Suite 210 

Durham, NC 27701 
 Attn: XXX 

Rock Springs Capital Master Fund LP 
 Rock Springs Capital

 650 South Exeter Street Suite 1070 

 Baltimore, Maryland. 21202 

Attention: General Counsel 
 With copies by email as follows: 

XXX@rockspringscapital.com; XXX@rockspringscapital.com 

Adage Capital Partners, LP 
 200 Clarendon St, 52nd Floor 
 Boston, MA 02116 

HBM Healthcare Investments (Cayman) Ltd. 
 Attention: XXX

 Governors Square, Suite #4-212-2 

23 Lime Tree Bay Avenue 
 West Bay 

Grand Cayman, Cayman Islands 
 Pivotal Alpha Limited 

c/o 23/F Nan Fung Tower 
 88 Connaught Road C 

Central, Hong Kong 
 Attn: XXX

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]